Keyword: Bristol-Myers Squibb
In July, Merck’s Keytruda narrowly missed the mark in a head and neck cancer trial. Details of that miss are now here.
ESMO's research slate included some truly late-breaking data, plus numbers from some closely watched trials. Here's your need-to-know.
Immuno-oncology and immunotherapy are familiar term to cancer patients, they don't know much about specifics on treatments or genetic details.
Bristol-Myers' immunotherapy Opdivo cut the risk of a melanoma recurrence by 35% compared with its sister med Yervoy, a new study found.
Merck & Co. and Incyte unveiled closely watched data on a one-two punch with Keytruda and the experimental IDO1 inhibitor epacadostat.
A one-two punch with Bristol-Myers' Opdivo and Yervoy cut the risk of death by 37% for kidney cancer patients with a poor prognosis.
The outlook brightened today for Bristol-Myers Squibb’s Opdivo-Yervoy combo with new results in a trial as a first-line treatment in kidney cancer.
After patient deaths cropped up in multiple myeloma studies featuring Merck’s Keytruda, the FDA isn’t taking any chances with Opdivo.
The new Havas Health & You is off to a solid start, especially considering the general downturn in the ad agency business for the first half of 2017.
Pfizer, Manhattan’s hometown drug company, has found brand-new digs, and they’ll be quite an improvement over its current 1960s-era HQ.